Physician profile
Derek Eibon
NPI 1295473692
$3,787.78
in general payments reported to CMS, 2019-2025
9 companies · $605 in 2025
The $605 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $821 · 2024: $2,170 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,596.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $1,307.65 | 2024 | |
| Biotissue Holdings INC. | $867.04 | 2023-2025 | |
| Alcon Vision LLC | $561.93 | 2023-2025 | Total30, Dailies Total1, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $443.01 | 2023-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $291.79 | 2022-2025 | Miebo, Xiidra |
| Oyster Point Pharma, INC. | $116.55 | 2023-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $95.11 | 2022-2025 | |
| Abbvie INC. | $80.55 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $24.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Eibon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.